Drug-Eluting Microsphere Bead Sizing for Tumor Core and Rim Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transarterial chemoembolization (TACE) procedures face challenges in accurately determining drug delivery to tumor areas, particularly with drug-eluting microsphere beads (DEBs) that are radio-lucent and have size limitations, making it difficult to target both the tumor core and rim effectively and achieve sufficient drug concentrations.
Innovation Solution
A system utilizing a combination of differently sized drug-eluting microsphere beads with distinct contrast agents and x-ray energies for spectral CT imaging to visualize and quantify drug delivery, allowing for precise targeting and measurement of drug concentrations in tumor regions, including the use of larger beads for embolizing feeding vessels and smaller beads for penetrating tumor core vessels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Length of moving object
If smaller drug-eluting microsphere beads (75-150 microns) are used to improve tumor penetration, then better tumor core delivery is achieved, but drug payload capacity and ability to embolize larger feeding vessels decrease
Solution Approach 1:
The patent divides the treatment approach into two distinct bead size segments: larger beads (100-300 microns) for embolizing feeding vessels and delivering high drug payload, and smaller beads (75-150 microns) for penetrating tumor core vessels. This segmentation allows each bead size to optimize its specific function without compromise.
Solution Approach 2:
The patent applies different bead sizes to different anatomical locations within the tumor vasculature: larger beads are used in larger feeding vessels where embolization and high drug delivery are priorities, while smaller beads are used in smaller tumor core vessels where penetration is the priority. This local quality approach matches bead properties to local requirements.
2Object-affected harmful factors
If radio-lucent DEBs are used to reduce systemic exposure, then enhanced tumor site efficacy is achieved, but ability to determine actual drug delivery to tumor is lost
Solution Approach 1:
The patent incorporates radio-opaque contrast agents into the DEBs, making them visible on x-ray and CT imaging. This allows direct visualization of bead deposition location and quantity, providing accurate measurement of drug delivery while maintaining the localized tumor-site action that reduces systemic exposure.
Solution Approach 2:
The patent uses radio-opaque contrast agents as an intermediary marker that correlates with drug presence. The contrast agent provides a measurable signal that indirectly indicates where and how much drug has been delivered, solving the measurement problem without affecting the drug's therapeutic function.
3Ease of operation
If uniform drug delivery is applied to entire tumor, then simplified treatment protocol is achieved, but inability to address different microenvironments of tumor core and rim effectively occurs
Solution Approach 1:
The patent delivers different drugs via different bead sizes to different tumor regions: larger beads with specific drugs target the tumor rim and feeding vessels, while smaller beads with different drugs target the tumor core. This local quality approach addresses the different microenvironments (oxygenation, cell density, vessel size) of core and rim regions effectively.
Solution Approach 2:
The patent segments the tumor treatment into distinct regions (core and rim) with different drug delivery strategies, using differently sized beads to achieve spatial differentiation of drug distribution according to local physiological conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate visualization and quantification of drug delivery, allowing for optimized drug dosing and reduced side effects by ensuring precise targeting of both tumor core and rim with different drugs, enhancing treatment efficacy while minimizing systemic exposure.
Implementation Method 1
drug-eluting microsphere beads (DEBs) are small beads with a shell and a core which may be loaded with a drug, such as chemotherapeutic agents, or other materials and which are capable of delivering the load in a reproducible manner
Implementation Method 2
a new kind of DEB was developed that is inherently radio-opaque and thus provides direct visualization of bead deposition. In this case radio opacity in the target region is directly related to drug dose
Implementation Method 3
The imaging system is arranged to obtain a first image data set of the region of interest with at least a first x-ray radiation energy and a second image data set of the region of interest with at least a second x-ray radiation energy
Data Source
AI summary
The present invention is directed towards a system and method for transarterial chemoembolization using differently sized drug-eluting microsphere beads filled with drugs and determining a delivered drug concentration using an imaging system.